Navigation Links
Barr Pharmaceuticals, Inc. Executive Bios
Date:3/28/2008


MONTVALE, N.J., March 28 /PRNewswire/ --

Christine A. Mundkur, Esq.

Chief Executive Officer,

Barr Laboratories, Inc.

-- In this newly created position, Mundkur has responsibility for Barr's

global generics business, including strategic planning, research and

development, regulatory affairs, operations, quality, and sales and

marketing. Under her leadership, Barr Laboratories will continue to

support the proprietary business in the areas of formulation,

regulatory affairs, and product supply.

-- Most recently served as Executive Vice President, Global Quality,

Safety and Regulatory Affairs, with responsibility for leading the

Company's Global Quality, Safety, PK/BE and Regulatory Affairs

Operations.

-- Barr: 15 years

* Joined Barr In 1993 As An Associate Counsel.

* Named Director Of Regulatory Affairs and Regulatory Counsel In

1997.

* Promoted to Vice President, Quality And Regulatory Counsel In 1998.

* Promoted to Sr. Vice President Quality and Regulatory Counsel in

2001.

* Promoted to Executive Vice President In 2007.

-- Bachelor of Science in Chemistry from Saint Louis University.

-- Juris Doctorate from Saint Louis University School of Law.

G. Frederick Wilkinson

Chief Executive Officer,

Duramed Pharmaceuticals, Inc.

-- In this newly created position, Wilkinson has responsibility for all

functions related to product selection, clinical development, and sales

and marketing. He will also continue directing Barr's growing global

biologics development program and for providing the strategic direction

and coordination of the Company's global business development

activities for our generic, proprietary and biologics activities.

-- Most recently served as President and Chief Operating Officer of

Duramed Pharmaceuticals, Inc., the proprietary products subsidiary of

Barr Pharmaceuticals, Inc.

-- Barr: 2 years

* Joined Barr in 2006.

* Prior to joining Barr, Wilkinson served as Chief Executive Officer,

President and a member of the Board of Directors of Columbia

Laboratories.

* From 1996 to 2001, Wilkinson was Watson Pharmaceuticals' Chief

Operating Officer and Senior Vice-President.

* Prior to joining Watson, Wilkinson spent 16 years at Sandoz

Pharmaceutical Corporation in numerous senior managerial positions

of increasing responsibility.

-- M.B.A. from Capital University.

-- B.S. in Pharmacy from Ohio Northern University.

Michael J. Bogda

President and Chief Operating Officer,

Barr Laboratories, Inc.

-- In his new position, Bogda will continue to oversee all aspects of

Global Product Supply and has expanded responsibilities for Quality and

Pharma Chemicals. In addition to his operational oversight

responsibilities, Bogda will also participate in the Company's

budgeting, financial forecasting and capital management activities.

-- Most recently served as Executive Vice President, Global Product Supply

("GPS") with responsibility for managing the Company's GPS team,

including the operational areas of manufacturing, engineering,

distribution, order processing, packaging, validation and process

technical services, project management and supply chain.

-- Barr: 7 years

* Joined Barr in 2000 as Vice President of Validation and Technical

Services and held various positions of increasing responsibility

with the Company.

* 2001 Promoted to Senior Vice President, Manufacturing and

Engineering.

* 2007 Promoted to Executive Vice President, Global Product Supply.

* Prior to joining Barr, Bogda served as Vice President Operations

and Facility General Manager at Copley Pharmaceutical Inc. where

he managed the consolidation and integration of Copley's

manufacturing plants after the company's acquisition by Teva

Pharmaceuticals USA.

* Bogda served on the Executive Management Committee at Copley

Pharmaceuticals.

-- Master of Science in Chemical Engineering from Rutgers University

College of Engineering.

-- Master of Business Administration from the Wharton School.

Timothy B. Sawyer

Executive Vice President,

Global Generic Sales and Marketing,

Barr Laboratories, Inc.

-- As Executive Vice President, Global Generic Sales and Marketing

Operations, Timothy Sawyer has responsibility for the Company's generic

commercial operations for Europe/Rest of World ("ROW") and the U.S.

-- Most recently served as Barr's Senior Vice President of European

Commercial Development, with responsibility in the European and ROW

markets for all sales and marketing activities, including coordinating

business development activities among the country managers to enhance

Barr's product portfolio and increase profitability throughout the

European/ROW markets.

-- Barr: 15 years

* Joined Barr in 1993 as Manager, Sales Administration.

* Promoted to the position of Associate Director New Business

Development in 1996.

* Promoted to Director of Sales Administration and New Business

Development in 2000.

* Named Vice President in 2001.

* Promoted to Senior Vice President in November 2006.

* Prior to joining Barr, Sawyer was associated with the law firm of

Winston & Strawn.

-- Bachelors Degree from the University of Richmond.


'/>"/>
SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Alseres Pharmaceuticals, Inc. Raises $5 Million
2. Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation
3. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
4. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
5. Renhuang Pharmaceuticals, Inc. Retains CCG Elite
6. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
7. Jazz Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 13, 2008
8. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
9. Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR
10. Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR
11. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... CITY, Utah (PRWEB) , ... April 21, 2017 ... ... of wilderness therapy treatment for adolescents and young adults, has kicked off its ... 20th-Sunday, April 23rd. This year’s theme is “Attachment Informed Therapy for Mental ...
(Date:4/21/2017)... , ... April 21, 2017 , ... The Patient Advocacy ... Health System, with the 2017 Ruth Ravich Patient Advocacy Award in recognition ... advocates. DeVaro was honored with the award at The Beryl Institute’s annual Patient ...
(Date:4/21/2017)... ... ... Alive for Wellness is a group of clinical professionals and ... Alive team uses advanced behavioral sciences treatment modalities to accomplish their goals. ... struggle is based on 10 modalities of treatment that include: , ...
(Date:4/21/2017)... Ramon, CA (PRWEB) , ... April 21, 2017 , ... ... might not understand the estate planning process, or where to even begin. “Now more ... unresolved if you are to properly protect yourself and your family,” said attorney Lisa ...
(Date:4/21/2017)... ... , ... During April 21-23, Super-Sod will join the vendor market of the ... everyone — from the avid gardener to the landscape admirer — during the three-day ... in a grand venue, and we are certainly looking forward to participating in this ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  Vanderbilt University Medical Center ... in Nashville , Tennesse have been ... Sphincter Stimulation for GERD (LESS GERD) trial. The EndoStim ... long-term reflux control by restoring normal function to the ... million people in the United States ...
(Date:4/19/2017)... 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and other unmet ... previously announced underwritten public offering of 23,625,084 shares ... price of $2.00 per share, before deducting underwriting ... by Sorrento.  The net proceeds to Sorrento from ...
(Date:4/19/2017)...  New research provides evidence that an old drug may ... study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... disease, the oral drug levodopa has long been considered the ... the disease progresses, the effects of the medication can partially ...
Breaking Medicine Technology: